Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endogenous Mechanisms of Inactivation of the Endothelium Tumor (BreastIls)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03667612
Recruitment Status : Active, not recruiting
First Posted : September 12, 2018
Last Update Posted : September 12, 2018
Sponsor:
Collaborator:
Institut de Biologie de Lille
Information provided by (Responsible Party):
Centre Oscar Lambret

Brief Summary:

The role of immunity in the development of cancers, and the associated escape mechanisms, have attracted renewed interest since the publication of tests testing immunological checkpoint inhibitors. One of the steps in the probably least studied immunological response is the penetration of immunocompetent cells within the tumor across the vascular barrier. This infiltration is suggested as a prognostic and predictive marker of treatment response, particularly in triple negative HER2 (Human Epidermal Growth Factor Receptor-2) overexpressing breast cancers. The methods of evaluating these infiltrates are complex and have been the subject of recommendations.

A better understanding of the mechanisms of infiltration of immunity cells within tumors will certainly help to better understand the impact of cancer treatments and develop new therapeutic strategies.

It is this issue of vascular endothelium that Dr. Soncin's team is developing as part of an INCa (Institut National du cancer) project. The egfl7 / VE-statin (vascular endothelial-statin) gene is thought to be involved in transendothelial passage of immune cells from vascular lumen to tumor. Its expression has already been studied in a series of breast cancers. Other markers of endothelial activation are currently being identified.

The main objective of this project will be to better understand the behavior of the endothelium in a population of breast cancer where the infiltrate in immune cells is precisely likely to play a leading role. This retrospective cohort of 250 to 300 cases treated with adjuvant and neoadjuvant will be immunologically characterized using the recommendations of Salgado et al. that a multicentric team of pathologists will take ownership. This evaluation will be counter-appraised.

Once our cohort is immunologically characterized, our project will focus on better understanding the endothelial mechanisms involved: which cells? immunophenotyping of immunity cells. By which vessels? (measurement of densities in blood and lymphatic vessels, density in HEV). By what mechanisms? Do the actors identified in vitro within the Inca project have an in vivo translation


Condition or disease
Breast Cancer Colon Cancer

Detailed Description:

The main objective of this project will be to better understand the behavior of the endothelium in a population of breast cancer where the infiltrate in immune cells is precisely likely to play a leading role. This retrospective cohort of 250 to 300 cases treated with adjuvant and neoadjuvant will be immunologically characterized using the recommendations of Salgado et al., that a multicentric team of pathologists will take ownership. This evaluation will be counter-appraised.

Once our cohort is immunologically characterized, our project will focus on better understanding the endothelial mechanisms involved: which cells? immunophenotyping of immunity cells. By which vessels? (measurement of densities in blood and lymphatic vessels, density in HEV). By what mechanisms? Do the actors identified in vitro within the Inca project have an in vivo translation


Layout table for study information
Study Type : Observational
Actual Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Endogenous Mechanisms of Inactivation of the Endothelium Tumor
Actual Study Start Date : January 31, 2018
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : October 2019

Resource links provided by the National Library of Medicine


Group/Cohort
Patients with breast cancer
  • Patients clinical data collection
  • Selection of patients tumor samples and centralization at the Oscar Lambret and the Henri Becquerel centres
  • Realization of tumor samples series of cuts and paraffin shavings for:

    • Quantitative RT-PCR (Reverse Transcription PCR): Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5 (SET Domain Containing 5), other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
    • Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes available)
    • Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies available)
    • Characterization of lymphocyte populations
    • Measurement of the endothelial cell density, the lymphatic endothelium and the "High Endothelial Venules"
Patients with colorectal cancer
  • Patients clinical data collection
  • Selection of patients tumor samples and centralization at the Oscar Lambret Center and the Henri Becquerel Center by the teams of Dr. Yves-Marie Robin and Jean-Michel Picquenot, Head of the Anatomy and Cytopathology Departments
  • Realization of series of cuts and paraffin shavings of the tumor samples for:

    • Quantitative RT-PCR: Assessment of the expression of the genes regulating the endothelium activation: egfl7, SetD5, other genes and microRNAs identified in the high-throughput screen realized by the Dr. F Soncin
    • Semi-quantitative evaluation of the same genes expression by in situ hybridization techniques (if probes are available)
    • Semi-quantitative evaluation of the expression of the corresponding proteins by immunohistochemistry techniques (If antibodies are available)
    • Characterization of lymphocyte populations
    • Measurement of the endothelial cell density, the lymphatic endothelium and the "High Endothelial Venules"



Primary Outcome Measures :
  1. correlation between the expression levels of the genes involved in the regulation of endothelial activation and the degree of tumor-infiltrating lymphocytes [ Time Frame: 24 months ]

    The expression of the genes (egfl7, SetD5, other genes and microRNAs) will be evaluated quantitatively by RT-PCR. The amount of RNA obtained corresponds to a relative amount of RNA relative to the amount of RNA measured in a sample used as a reference.

    A semi-quantitative evaluation will also be carried out by in situ hybridization techniques and immunohistochemistry of endothelial expression of endothelial activation regulation markers: 0+ no labeled vessels, 1+ <30% of labeled vessels, 2+ between 30 and 60% of marked vessels, 3+> 60% of marked vessels The lymphocyte infiltration will be evaluated by measuring the ratio between the surface infiltrated by mononuclear cells and the tumor surface (for intratumoral TILS) or stromal (for total stromal TILS). The analysis will be done on H & E slides and the data will be expressed as a percentage.



Secondary Outcome Measures :
  1. reproducibility of lymphocyte infiltration assessment on H & E slides [ Time Frame: 24 months ]
  2. study of the subgroups of the cohort with a predominant lymphocytes infiltration cancer [ Time Frame: 24 months ]
    description of subpopulations of immunocompetent cells by specific complementary immunolabeling of CD4 + T lymphocytes (mature T helper lymphocytes expressing the surface protein CD4), cytotoxic CD8 (T lymphocytes expressing the surface protein CD8), T-regulatory (CD25 / FoxP3), B-cell lymphocytes , macrophages and NK (Natural Killer) cells

  3. Cell density description [ Time Frame: 24 months ]
    Description of density in vascular endothelial (CD31 / 34 labeled), lymphatic (LYVE / podoplanin-labeled) and HEV (High endothelial venom MECA79 + (Rat Monoclonal Anti-Peripheral Node Addressin Antibody )) cells and correlation with lymphocyte infiltrate levels

  4. Prognostic value assessment [ Time Frame: 24 months ]
    Evaluate the prognostic value of biomarkers and lymphocytic infiltrate in terms of Global Survival and Survival Without Recurrence

  5. Expression levels of genes involved in the regulation of endothelial activation [ Time Frame: 24 months ]
    In subpopulations of patients treated in neo-adjuvant or metastatic situations: assess the expression levels of genes involved in the regulation of endothelial activation

  6. treatment response data [ Time Frame: 24 months ]
    In subpopulations of patients treated in neo-adjuvant or metastatic situations: assess the treatment response data (chemotherapy in patients with breast cancer, chemotherapy and antiangiogenic in colon cancers)

  7. lymphocytic infiltrate data [ Time Frame: 24 months ]
    For patients treated for breast cancer: study lymphocytic infiltrate data

  8. the existence of a BRCA1 and or BRCA 2 mutation (which are tumour suppressor genes) [ Time Frame: 24 months ]
    For patients treated for breast cancer: assess the existence of a BRCA1 and or BRCA 2 mutation

  9. association between lymphocytic infiltrate data and the RER phenotype (the replication error phenotype) [ Time Frame: 24 months ]
    For patients treated for colon cancer: to study the association between lymphocytic infiltrate data and the RER phenotype

  10. The RER phenotype (the replication error phenotype) [ Time Frame: 24 months ]
    For patients treated for colon cancer: to study the RER phenotype


Biospecimen Retention:   Samples With DNA
DNA from tumor samples


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with:

  • a breast cancer
  • a colorectal cancer
Criteria

Inclusion Criteria:

  • Men and women aged 18 and over
  • Confirmed histological diagnosis of breast carcinoma at localized or metastatic stage or colorectal cancer
  • Treated at the Oscar Lambret Center or the Henri Becquerel Center between 1/1/2005 and 31/12/2007
  • Having undergone surgery for excision of the primary tumor and / or a metastasis
  • resected specimen available
  • Patients who gave their consent

Exclusion Criteria:

  • History of other cancers
  • Breast or colic tumors with other histological profiles
  • Patient treated for breast or colonic recurrence

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03667612


Locations
Layout table for location information
France
Centre Oscar Lambret
Lille, France
Centre Henri Becquerel
Rouen, France
Sponsors and Collaborators
Centre Oscar Lambret
Institut de Biologie de Lille
Investigators
Layout table for investigator information
Principal Investigator: Géraldine Lauridant, MD Centre oscar Lambret de Lille

Layout table for additonal information
Responsible Party: Centre Oscar Lambret
ClinicalTrials.gov Identifier: NCT03667612     History of Changes
Other Study ID Numbers: BreastIls-1605
First Posted: September 12, 2018    Key Record Dates
Last Update Posted: September 12, 2018
Last Verified: August 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No